Cargando…

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016

Nonalcoholic steatohepatitis (NASH)-related cirrhosis and cryptogenic cirrhosis (CC) have become leading indications for liver transplantation (LT) in the US. Our aim was to compare the trends, clinical presentation, and outcomes for transplant candidates with NASH and CC. The Scientific Registry of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golabi, Pegah, Bush, Haley, Stepanova, Maria, Locklear, Cameron T., Jacobson, Ira M., Mishra, Alita, Trimble, Gregory, Erario, Madeline, Venkatesan, Chapy, Younossi, Issah, Goodman, Zachary, Younossi, Zobair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081090/ https://www.ncbi.nlm.nih.gov/pubmed/30075518 http://dx.doi.org/10.1097/MD.0000000000011518

Ejemplares similares

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study
por: Younossi, Zobair M, et al.
Publicado: (2014)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Exercise as an intervention for patients with end-stage liver disease: Systematic review
por: Locklear, Cameron T., et al.
Publicado: (2018)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
por: Golabi, Pegah, et al.
Publicado: (2019)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
por: Paik, James M, et al.
Publicado: (2020)

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017
por: Paik, James M., et al.
Publicado: (2021)

Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis
por: Stepanova, Maria, et al.
Publicado: (2015)

The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19
por: Stepanova, Maria, et al.
Publicado: (2022)

Synchronous Hepatocellular Carcinoma and Cholangiocarcinoma in a Patient Transplanted for Cryptogenic Cirrhosis
por: Geramizadeh, B., et al.
Publicado: (2014)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Occult Hepatitis C Virus Infection in Candidates for Liver Transplant With Cryptogenic Cirrhosis
por: Keyvani, Hossein, et al.
Publicado: (2013)

Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study
por: Fukushima, Masanori, et al.
Publicado: (2022)

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
por: Shahab, Omer, et al.
Publicado: (2019)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Sarcopenia, healthy living, and mortality in patients with chronic liver diseases
por: Van Dongen, Catherine, et al.
Publicado: (2022)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor
por: Stepanova, Maria, et al.
Publicado: (2016)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
por: Golabi, Pegah, et al.
Publicado: (2016)

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
por: Golabi, Pegah, et al.
Publicado: (2020)

The impact of hepatocellular carcinoma diagnosis on patients' health‐related quality of life
por: Verma, Manisha, et al.
Publicado: (2021)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

The association of Familial Mediterranean Fever and cryptogenic cirrhosis
por: Baskin, E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ncvec0iht0oj7igjqh3u965hgt